Atamyo Therapeutics News and Activities

View the org chart displaying its 7 main executives

Most searched biographies at Atamyo Therapeutics

• Stéphane Degove, Chief Executive Officer
• Roger Hajjar, Director
• Frédéric Revah, Director

Create your alert
to follow the executive moves at Atamyo Therapeutics.

Atamyo Therapeutics has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Atamyo Therapeutics

• Atamyo Therapeutics obtient l’autorisation réglementaire aux Etats-Unis pour l’essai clinique de ATA-200, sa thérapie génique pour traiter la myopathie des ceintures LGMD-2C/R5 - Atamyo Therapeutics
• IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA - Atamyo Therapeutics
• Atamyo Therapeutics Observes LGMD Awareness Day with Updates on Key Milestones in its Clinical Development of Gene Therapies for Patients Suffering from Limb-Girdle Muscular Dystrophies - Atamyo Therapeutics
• Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe - Atamyo Therapeutics
• Atamyo Therapeutics présentera un update Corporate et les avancées de son pipeline lors de 6 conférences à venir aux États-Unis et en Europe - Atamyo Therapeutics
• The Dion Foundation and Atamyo Therapeutics Announce a Partnership to Expand into the US Atamyo’s Clinical Trial of ATA-200 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - Atamyo Therapeutics
• La Dion Foundation et Atamyo Therapeutics annoncent un partenariat pour étendre aux États-Unis l’essai clinique d’Atamyo sur la thérapie génique ATA-200 pour traiter la myopathie des ceintures LGMD-2C/R5 - Atamyo Therapeutics
• Atamyo Therapeutics Obtains US FDA Fast Track Designation  for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) - Atamyo Therapeutics
• Atamyo Therapeutics annonce des présentations scientifiques sur ses programmes LGMD et sa participation à des conférences - Atamyo Therapeutics
• Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - Atamyo Therapeutics
• View more press releases Close

Social media about Atamyo Therapeutics

• Atamyo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Atamyo Therapeutics on LinkedIn, Twitter & YouTube